Abstract
This article presents the case of a 31-year old patient with alopecia areata, who after two subsequent treatments with Janus kinase-inhibitors Baricitinib and Abrocitinib, achieved therapeutic success after using tofacitinib. This case raises the question, whether tofacitinib could be a valid treatment option for the future.